Improving CML Outcomes: Nordic CML Study Group Shares New ASH 2025 Insights

In this MEDtalk, Henrik Hjort-Hansen, Department of Hematology, St. Olavs Hospital HF, Trondheim, presents results from the Norwegian Bosupeg trial conducted within the Nordic CML Study Group. The study evaluated the efficacy and tolerability of combined treatment with bosutinib and low-dose ropeginterferon alfa-2b in patients with chronic myeloid leukemia (CML). The data were presented at the American Society of Hematology (ASH) Annual Meeting 2025 in Orlando, Florida.